Correction: Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting
J. Opie, Z. Mohamed, D. Chetty, J. Bailey, K. Brown, E. Verburgh, D. Hardie
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsViral-associated cancers and disorders · HIV Research and Treatment · T-cell and Retrovirus Studies
Correction to: Clinical and Experimental Medicine (2024) 25:10
https://doi.org/10.1007/s10238-024–01524-8.
In the original version of the article, the entries in Table 1 was misaligned.
Table 1 which previously appeared as
Table 1. Baseline characteristics of Hodgkin lymphoma patientsTotal cohortn = 68HIV+ ven=21 (31%)HIV- ven=47 (69%)P-valueFemale34 (51%)10 (48%)24 (51%)0.793Median age (years)36(IQR 26 – 52)39(IQR 28–46)33(IQR 25–57)0.841PLWH receiving ART18 (86%)CD4 count median (cells/ul) <100100–200>200152 (IQR 105–286)5 (25%)6 (30%)9 (45%)EBV tumour positive33 (49%)20 (95%)13 (28%)<0.001Stage at diagnosisIIIIIIIV1 (2%)13 (19%)9 (13%)45 (66%)04 (19%)1 (5%)16 (76%)1 (2%)9 (19%)8 (17%)29 (62%)0.552Histological subtypeNodular sclerosingLymphocyte richMixed cellularityLymphocyte depletedCHL unclassified37 (54%)12 (18%)10 (15%)1 (1%)8 (12%)6 (29%)2 (10%)5 (24%)1 (5%)7 (33%)31 (66%)10 (21%)5 (11%)01 (2%)<0.001Chemotherapy treatmentDied before treatment/no treatmentFirst line onlyFirst & second line1 (1%)52 (76%)15 (22%)1 (5%)17 (81%)3 (14%)035 (74%)12 (26%)0.244Survival at last follow upAliveDeceased56 (82%)12 (18%)14 (67%)7 (33%)42 (89%)5 (11%)0.037ART antiretroviral therapy; CHL classical Hodgkin lymphoma; PLWH people living with HIV; IQR interquartile range*1 patient did not have a CD4 count available**Detected by EBERish (for lymph node and tissue) and LMP-1 staining (for bone marrow biopsies)***All CHL unclassified cases were diagnosed on bone marrow biopsy
But should have been
Table 1. Baseline characteristics of Hodgkin lymphoma patientsTotal cohortn = 68HIV+ ven=21 (31%)HIV- ven=47 (69%)P-valueFemale34 (51%)10 (48%)24 (51%)0.793Median age (years)36(IQR 26 – 52)39(IQR 28–46)33(IQR 25–57)0.841PLWH receiving ART18 (86%)CD4 count median (cells/ul) * <100 100–200 >200152 (IQR 105–286)5 (25%)6 (30%)9 (45%)EBV tumour positive33 (49%)20 (95%)13 (28%)<0.001Stage at diagnosis I II III IV1 (2%)13 (19%)9 (13%)45 (66%)04 (19%)1 (5%)16 (76%)1 (2%)9 (19%)8 (17%)29 (62%)0.552Histological subtypeNodular sclerosingLymphocyte richMixed cellularityLymphocyte depletedCHL unclassified*37 (54%)12 (18%)10 (15%)1 (1%)8 (12%)6 (29%)2 (10%)5 (24%)1 (5%)7 (33%)31 (66%)10 (21%)5 (11%)01 (2%)<0.001Chemotherapy treatmentDied before treatment/no treatment First line only First & second line1 (1%)52 (76%)15 (22%)1 (5%)17 (81%)3 (14%)035 (74%)12 (26%)0.244Survival at last follow up Alive Deceased56 (82%)12 (18%)14 (67%)7 (33%)42 (89%)5 (11%)0.037
The original version of this article has been corrected.